Cardiomyopathy Clinical Trials 2023

What Are Cardiomyopathy Clinical Trials?

The term "cardiomyopathy" refers to a group of heart muscle diseases. These diseases can affect people of different ages and races and have various causes, indicators, and treatments.

During Cardiomyopathy, the heart's normal muscle may stiffen, thin out, thicken, or fill with bodily substances that don't belong there. Due to this, the heart’s capacity to pump blood is lowered, which can cause irregular heartbeats, the pooling of blood in the lungs or other parts of the body, and even heart failure. Cardiomyopathy may be hereditary or acquired, meaning it may occur due to another condition, illness, or circumstance. It's not always possible to point out the exact cause.

Cardiomyopathy clinical trials are scientific investigations into this disease's treatment, diagnosis, or prevention. They provide crucial information, whether the findings are favorable or unfavorable, for patients with cardiovascular disease and the doctors who treat them.

Why Is Cardiomyopathy Being Studied Through Clinical Trials?

It is now possible to find potentially effective treatments and carry out suitably planned Cardiomyopathy clinical trials to influence the natural course of the disease, relieve symptoms, and enhance the patient's quality of life. This is due to significant advances in understanding Cardiomyopathy and growing networking opportunities among international referral centers.

What Are the Types of Treatments Available for Cardiomyopathy?

The type of Cardiomyopathy will affect the course of treatment. Cardiomyopathy treatment aims to manage symptoms, reduce the progression of the illness, and prevent unexpected death. If you start showing symptoms of Cardiomyopathy, your doctor may advise you to alter your diet and physical exercise, minimize stress, abstain from alcohol and drugs, and take medications. If any diseases contributed to your Cardiomyopathy, your doctor may also treat them and suggest arrhythmia correcting and blood flow-improving devices. A heart transplant or open-heart surgery is often the last resort.

What are Some Recent Breakthrough Clinical Trials for Cardiomyopathy?

The following clinical trials offer significant results for treating Cardiomyopathy:

2006: Cell Therapy In Dilated Cardiomyopathy – This protocol outlines a randomized, double-blind, placebo-controlled clinical trial to assess the effectiveness of bone marrow-derived stem cell implants in patients with dilated Cardiomyopathy and heart failure classified as class III or IV by the New York Heart Association. The main goal of this study is to determine whether the autologous bone marrow stem cell implant increases the left ventricle's ejection fraction compared to a control group in patients receiving the optimal treatment for dilated Cardiomyopathy.

2020: Efficacy of Immunosuppression in Myocarditis or Inflammatory Cardiomyopathy - This multicenter, randomized, prospective, double-blind, placebo-controlled trial's goal is to evaluate the effectiveness and safety of a 12-month course of azathioprine and prednisone for patients with biopsy-proven virus-negative myocarditis or inflammatory Cardiomyopathy and reduced ejection fraction, compared to a placebo. The study will determine whether the effects of the treatment are still present a year later.